Treating severe asthma

Working with your healthcare team will help you find the best possible treatments

Treating severe asthma

It’s true that severe asthma can be harder to manage, but there are still lots of ways you can get more control over your symptoms, working in partnership with your healthcare team.

These days, there are a lot of treatment options available. And researchers are working on new treatments for severe asthma.

This section is a guide to what you need to know about the treatments your healthcare team might suggest.

How is severe asthma treated?

You’ll be working alongside your healthcare professional to find the right combination of treatments to get the best possible control over your asthma symptoms. This page looks at the medicines you may try to help you manage your asthma, from steroids to newer treatments such as the ‘mab’ class of drugs.

Steroids in the long term

Lots of people with asthma take low doses of steroids in preventer inhalers. But some people with severe asthma also need to take higher doses as tablets to help control their symptoms. Find out the proven facts about long-term steroid tablets and how to make sure you’re on the lowest dose possible. There’s also a useful section about how to manage possible side effects.

Xolair and new treatments 

Scientists are always working on new ways to treat asthma. The latest treatments are medicines called monoclonal antibodies – which include Xolair (omalizumab) and and Nucala (mepolizumab). Find out how these medicines work and whether they might help you.

Bronchial thermoplasty (BT)

BT is a treatment suitable for some adults with severe asthma. You can find out all about this hospital procedure here.

Finding a cure for severe asthma

Asthma UK is working with scientists, researchers and people with asthma to find new treatments for severe asthma, and ultimately, a cure. In our landmark report, Severe Asthma we explain how we’re working towards this goal and how it will help people to live longer and live better.

Last updated March 2017

Next review due October 2019